BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
2 Ni Y, Nagashimada M, Zhuge F, Zhan L, Nagata N, Tsutsui A, Nakanuma Y, Kaneko S, Ota T. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E. Sci Rep. 2015;5:17192. [PMID: 26603489 DOI: 10.1038/srep17192] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 19.5] [Reference Citation Analysis]
3 Ilan Y. Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Aliment Pharmacol Ther 2016;44:1168-82. [PMID: 27778363 DOI: 10.1111/apt.13833] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
4 Colca JR. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opinion on Drug Discovery 2015;10:1259-70. [DOI: 10.1517/17460441.2015.1100164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab 2014;25:576-85. [PMID: 25183341 DOI: 10.1016/j.tem.2014.08.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
6 Narayanan S, Surette FA, Hahn YS. The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Netw 2016;16:147-58. [PMID: 27340383 DOI: 10.4110/in.2016.16.3.147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
7 Steinman JB, Salomao MA, Pajvani UB. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. Liver Int 2021. [PMID: 34328687 DOI: 10.1111/liv.15025] [Reference Citation Analysis]
8 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 339] [Article Influence: 72.4] [Reference Citation Analysis]
9 Svendsen P, Graversen JH, Etzerodt A, Hager H, Røge R, Grønbæk H, Christensen EI, Møller HJ, Vilstrup H, Moestrup SK. Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes. Mol Ther Methods Clin Dev 2017;4:50-61. [PMID: 28344991 DOI: 10.1016/j.omtm.2016.11.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
10 Dattaroy D, Seth RK, Das S, Alhasson F, Chandrashekaran V, Michelotti G, Fan D, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. Am J Physiol Gastrointest Liver Physiol. 2016;310:G510-G525. [PMID: 26718771 DOI: 10.1152/ajpgi.00259.2015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
11 Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36:936-948. [PMID: 26972930 DOI: 10.1111/liv.13115] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
12 Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, van der Merwe S, Bedossa P, Nevens F, Cammue B, Thevissen K, Cassiman D. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46. [PMID: 28231800 DOI: 10.1186/s12944-017-0432-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
13 Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3:212-32. [PMID: 28691103 DOI: 10.18053/jctres.03.2017S1.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
14 Cotter DG, Ercal B, Huang X, Leid JM, d'Avignon DA, Graham MJ, Dietzen DJ, Brunt EM, Patti GJ, Crawford PA. Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest 2014;124:5175-90. [PMID: 25347470 DOI: 10.1172/JCI76388] [Cited by in Crossref: 96] [Cited by in F6Publishing: 67] [Article Influence: 13.7] [Reference Citation Analysis]
15 Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One 2018;13:e0194568. [PMID: 29847555 DOI: 10.1371/journal.pone.0194568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zhang H, Shen WJ, Li Y, Bittner A, Bittner S, Tabassum J, Cortez YF, Kraemer FB, Azhar S. Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. Nutr Metab (Lond) 2016;13:63. [PMID: 27708683 DOI: 10.1186/s12986-016-0121-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
17 Khoo NKH, Fazzari M, Chartoumpekis DV, Li L, Guimaraes DA, Arteel GE, Shiva S, Freeman BA. Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. Redox Biol 2019;22:101132. [PMID: 30769284 DOI: 10.1016/j.redox.2019.101132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
18 Brand JF, Furenlid LR, Altbach MI, Galons JP, Bhattacharyya A, Sharma P, Bhattacharyya T, Bilgin A, Martin DR. Task-based optimization of flip angle for fibrosis detection in T1-weighted MRI of liver. J Med Imaging (Bellingham) 2016;3:035502. [PMID: 27446971 DOI: 10.1117/1.JMI.3.3.035502] [Reference Citation Analysis]
19 Xu Z, Shi J, Yu D, Zhu L, Jia J, Fan J. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Adv Ther 2016;33:2069-81. [DOI: 10.1007/s12325-016-0416-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
21 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
22 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638-652. [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 14.9] [Reference Citation Analysis]
23 Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65-S75. [PMID: 25920092 DOI: 10.1016/j.jhep.2015.02.041] [Cited by in Crossref: 170] [Cited by in F6Publishing: 152] [Article Influence: 34.0] [Reference Citation Analysis]
24 Zhou C, Wang P, Lei L, Huang Y, Wu Y. Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signaling pathway. Aging (Albany NY) 2020;12:9066-84. [PMID: 32413869 DOI: 10.18632/aging.103172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chen L, Zhao X, Liang G, Sun J, Lin Z, Hu R, Chen P, Zhang Z, Zhou L, Li Y. Recombinant SFRP5 protein significantly alleviated intrahepatic inflammation of nonalcoholic steatohepatitis. Nutr Metab (Lond) 2017;14:56. [PMID: 28824700 DOI: 10.1186/s12986-017-0208-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
26 Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65. [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4] [Cited by in Crossref: 1241] [Cited by in F6Publishing: 624] [Article Influence: 177.3] [Reference Citation Analysis]
27 Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 2016;387:679-90. [DOI: 10.1016/s0140-6736(15)00803-x] [Cited by in Crossref: 762] [Cited by in F6Publishing: 330] [Article Influence: 152.4] [Reference Citation Analysis]
28 Cotter DG, Ercal B, d'Avignon DA, Dietzen DJ, Crawford PA. Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice. Am J Physiol Endocrinol Metab 2014;307:E176-85. [PMID: 24865983 DOI: 10.1152/ajpendo.00087.2014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
29 Chen XJ, Liu WJ, Wen ML, Liang H, Wu SM, Zhu YZ, Zhao JY, Dong XQ, Li MG, Bian L, Zou CG, Ma LQ. Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats. Sci Rep 2017;7:41144. [PMID: 28106137 DOI: 10.1038/srep41144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
30 Jacobs A, Warda A, Verbeek J, Cassiman D, Spincemaille P. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016;6:185-200. [DOI: 10.1002/cpmo.3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
31 Echeverría F, Valenzuela R, Espinosa A, Bustamante A, Álvarez D, Gonzalez-Mañan D, Ortiz M, Soto-Alarcon SA, Videla LA. Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: involvement of resolvins RvE1/2 and RvD1/2. J Nutr Biochem 2019;63:35-43. [PMID: 30321750 DOI: 10.1016/j.jnutbio.2018.09.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 16.0] [Reference Citation Analysis]
32 Schneck AS, Anty R, Patouraux S, Bonnafous S, Rousseau D, Lebeaupin C, Bailly-Maitre B, Sans A, Tran A, Gugenheim J, Iannelli A, Gual P. Roux-En Y Gastric Bypass Results in Long-Term Remission of Hepatocyte Apoptosis and Hepatic Histological Features of Non-alcoholic Steatohepatitis. Front Physiol. 2016;7:344. [PMID: 27594839 DOI: 10.3389/fphys.2016.00344] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
33 Verbeek J, Jacobs A, Spincemaille P, Cassiman D. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis. Curr Protoc Mouse Biol 2016;6:201-10. [PMID: 27248435 DOI: 10.1002/cpmo.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
34 Bando Y, Ogawa A, Ishikura K, Kanehara H, Hisada A, Notumata K, Okafuji K, Toya D. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus. Diabetol Int 2017;8:218-27. [PMID: 30603325 DOI: 10.1007/s13340-016-0302-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
35 Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32:329-34. [PMID: 27921044 DOI: 10.1159/000448940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
36 Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab. 2015;4:353-357. [PMID: 25830098 DOI: 10.1016/j.molmet.2015.01.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
37 Dongiovanni P, Meroni M, Baselli GA, Bassani GA, Rametta R, Pietrelli A, Maggioni M, Facciotti F, Trunzo V, Badiali S, Fargion S, Gatti S, Valenti L. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clin Sci (Lond) 2017;131:1301-15. [PMID: 28468951 DOI: 10.1042/CS20170175] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
38 Gan L, Xiang W, Xie B, Yu L. Molecular mechanisms of fatty liver in obesity. Front Med 2015;9:275-87. [PMID: 26290284 DOI: 10.1007/s11684-015-0410-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
39 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:1155-1161. [PMID: 24743428 DOI: 10.1161/atvbaha.114.303034] [Cited by in Crossref: 96] [Cited by in F6Publishing: 56] [Article Influence: 13.7] [Reference Citation Analysis]
40 Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015;9:629-50. [DOI: 10.1586/17474124.2015.965143] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
41 Tilg H, Moschen AR. Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov 2014;9:687-96. [PMID: 24766298 DOI: 10.1517/17460441.2014.911283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
42 Orsi E, Grancini V, Menini S, Aghemo A, Pugliese G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int. 2017;37:950-962. [PMID: 27943508 DOI: 10.1111/liv.13337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
43 Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs 2020;29:151-61. [PMID: 31847612 DOI: 10.1080/13543784.2020.1703949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]